Comparative Pharmacology
Head-to-head clinical analysis: GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE versus SILPHEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE versus SILPHEN.
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE vs SILPHEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Guaifenesin is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity. Dextromethorphan is a centrally acting cough suppressant that binds to NMDA receptors and sigma-1 receptors, elevating the cough threshold.
N-acetyl-para-aminophenol (APAP) is a centrally and peripherally acting analgesic and antipyretic. Its mechanism involves inhibition of cyclooxygenase (COX) in the central nervous system, reducing prostaglandin synthesis, and activation of descending serotonergic pathways. It does not significantly inhibit peripheral COX or platelet function.
For adults and children ≥12 years: 10 mL (200 mg guaifenesin, 20 mg dextromethorphan) orally every 4 hours, not to exceed 60 mL (1200 mg guaifenesin, 120 mg dextromethorphan) per 24 hours.
1-2 tablets (25-50 mg diphenhydramine HCl) orally every 4-6 hours as needed; maximum 300 mg/day.
None Documented
None Documented
Guaifenesin: 1-2 hours; Dextromethorphan: 3-6 hours (extensive metabolizers), 18-24 hours (poor metabolizers due to CYP2D6 polymorphism).
Terminal elimination half-life is 4-6 hours in patients with normal renal function; prolongs to 12-24 hours with creatinine clearance <30 mL/min.
Guaifenesin: ~60% renal (metabolites), ~35% fecal; Dextromethorphan: ~70% renal (parent and metabolites, 45% as unchanged dextrorphan), ~20% biliary/fecal.
Renal excretion accounts for 65% of the dose as unchanged drug; hepatic metabolism produces inactive glucuronide conjugates (20%), with biliary/fecal elimination comprising the remaining 15%.
Category C
Category C
Expectorant/Antitussive Combination
Expectorant